Yuchang Li

Mr. Yuchang Li

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
HLHai-Xin Liu
Hai-Xin Liu
XSXin-Lei Shi
Xin-Lei Shi
SZShu-Yuan Zhou
Shu-Yuan Zhou
YLYuchang Li
Yuchang Li
DLDong-Yan Lin
Dong-Yan Lin
SWShi-Yuan Wen
Shi-Yuan Wen
Background: Shenqi granule (SQG) was used clinically to strengthen the spleen and boost energy, alleviating physical weakness and limb fatigue caused by energy deficiency. However, the specific effects and potential molecular mechanisms of SQG in myocardial infarction (MI) treatment remain to be clarified. Methods: This study thoroughly evaluates SQG’s role in improving MIRI in rats using a biological approach. Network pharmacology, weighted gene co-expression network analysis (WGCNA), receiver operating characteristic (ROC), and immune landscape analysis were used to analyze components and key molecular targets. The therapeutic targets of SQG were then validated through molecular docking, molecular dynamics simulation, and experiments. Results: SQG reduced myocardial infarct size and improved myocardial function in rats. Network pharmacology analysis found that six bioactive compounds in SQG could target four proteins. Using WGCNA and ROC, two key targets of SQG were identified, MMP9 and ADH1C. Importantly, integrating PPI network prediction, molecular docking, and expression correlation analyses, MMP9 and ADH1C demonstrate strong physical binding potential and expression association, suggesting their possible involvement in MIRI-related pathways through the immune microenvironment. Molecular experiments and other methods confirmed that the five active ingredients in SQG (luteolin, quercetin, hederagenin, 7-O-methylisomucronulatol, and stigmasterol) can exert cardioprotective effects by stably binding to MMP9/ADH1C. Conclusions: SQG reduces myocardial infarct volume and enhances myocardial function in MIRI rats, likely via inhibiting MMP9 and ADH1C expression. This suggests SQG’s potential as a therapeutic agent for MI, with findings offering strong scientific support for SQG’s use in cardiovascular disease research.

21 October 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
HLHai-Xin Liu
Hai-Xin Liu
YLYuchang Li
Yuchang Li
CLCai xia Liu
Cai xia Liu
MYMingkuan Yang
Mingkuan Yang
SZShu-Yuan Zhou
Shu-Yuan Zhou
SWShi-Yuan Wen
Shi-Yuan Wen
Objective: Shenqi Granules is a traditional Chinese medicine formula derived from the classic prescription Shenqi Formula (SQF), composed of Astragali Radix (Huangqi) and Codonopsis Radix (Dangshen). SQF shows neuroprotection in cerebral ischemia-reperfusion injury (CIRI), but the underlying mechanisms remain unclear. Methods: The rat model of middle cerebral artery occlusion (MCAO) was established using the suture method to evaluate the neuroprotective effect of SQF. Blood-absorbed components were identified via UHPLC-Q-TOF-MS/MS, and potential targets and pathways were predicted through network pharmacology. Non-targeted metabolomics of serum and feces was performed using UHPLC-Orbitrap MS, and core metabolic pathways were selected based on regulation magnitude (RM). Gut microbiota structure was analyzed by 16S rRNA sequencing, with associations between microbiota and metabolites assessed via the Mantel test and redundancy analysis (RDA). Weighted gene co-expression network analysis (WGCNA) was applied to screen core Hub genes for ischemic stroke (IS). Based on single-cell RNA data, a uridine transport/metabolism-associated transcriptional signature score (Uridine_Score) was constructed, and cell type-specific coupling between glucocerebrosidase (GBA) and this transcriptional signature was analyzed. Microglial temporal trajectory analysis was conducted using Monocle3. Molecular docking between core components and GBA was verified by AutoDock, and GBA mRNA expression was confirmed by RT-qPCR. Results: High-dose SQF reduced infarct volume and neuronal damage and improved behavior. A total of 28 absorbed components and 31 shared IS targets were identified. Metabolomics revealed nucleotide metabolism as a core pathway common to both serum and fecal samples. SQF restored gut–blood uridine balance (serum uridine 0.41× Sham → 0.85× post-SQF), reduced fecal dTMP and hypoxanthine. 16S rRNA sequencing demonstrated that the overall correlation between microbial community structure and nucleotide metabolites was statistically significant (Mantel r = 0.307–0.321, p < 0.01). WGCNA highlighted GBA, MMP9, and PYGL. Single-cell analysis showed a microglia-specific uridine transport/metabolism-associated transcriptional signature post-stroke, with GBA most correlated with this signature (ρ = 0.377). Pseudotime revealed microglial state transitions (Homeostatic → Acute_Reactive → DAM), with positive GBA–uridine transport/metabolism-associated transcriptional coupling in the Homeostatic and DAM states. Riboflavin showed the strongest GBA binding (−9.83 kcal/mol), and SQF upregulated GBA mRNA in the penumbra (p < 0.0001). Conclusions: SQF reprograms nucleotide metabolism via the gut–blood axis and enhances microglial GBA–uridine transport/metabolism-associated transcriptional coupling.